[go: up one dir, main page]

AR095502A1 - Anticuerpos profármaco contra el inhibidor de la vía del factor tisular - Google Patents

Anticuerpos profármaco contra el inhibidor de la vía del factor tisular

Info

Publication number
AR095502A1
AR095502A1 ARP140101107A ARP140101107A AR095502A1 AR 095502 A1 AR095502 A1 AR 095502A1 AR P140101107 A ARP140101107 A AR P140101107A AR P140101107 A ARP140101107 A AR P140101107A AR 095502 A1 AR095502 A1 AR 095502A1
Authority
AR
Argentina
Prior art keywords
inhibitor
propharm
antibodies
antibodies against
prodrug
Prior art date
Application number
ARP140101107A
Other languages
English (en)
Inventor
Wang Zhuozhi
Murphy John
Hermiston Terry
Zhu Ying
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of AR095502A1 publication Critical patent/AR095502A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente divulgación proporciona anticuerpos profármaco que se unen específicamente al inhibidor de la vía del factor tisular (TFPI) únicamente tras la exposición a proteasas de la cascada de coagulación. Los anticuerpos profármaco descritos son útiles para tratar trastornos hemorrágicos, tales como hemofilia. Cuando se usa en dichos tratamientos, estos anticuerpos profármaco muestran una mayor semivida respecto a otros anticuerpos anti-TFPI a la vez que mitigan el potencial de efectos secundarios tales como trombosis.
ARP140101107A 2013-03-15 2014-03-14 Anticuerpos profármaco contra el inhibidor de la vía del factor tisular AR095502A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361794024P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR095502A1 true AR095502A1 (es) 2015-10-21

Family

ID=51537758

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101107A AR095502A1 (es) 2013-03-15 2014-03-14 Anticuerpos profármaco contra el inhibidor de la vía del factor tisular

Country Status (10)

Country Link
US (1) US20160009817A1 (es)
EP (1) EP2970498A4 (es)
JP (1) JP2016514687A (es)
CN (1) CN105209496A (es)
AR (1) AR095502A1 (es)
CA (1) CA2906095A1 (es)
HK (1) HK1215262A1 (es)
TW (1) TW201522368A (es)
UY (1) UY35459A (es)
WO (1) WO2014144689A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
EP3003370B1 (en) * 2013-05-28 2020-01-22 Dcb-Usa Llc Antibody locker for the inactivation of protein drug
CN107922506B (zh) 2015-08-19 2021-11-09 辉瑞公司 组织因子途径抑制剂抗体及其用途
WO2017087789A1 (en) 2015-11-19 2017-05-26 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
AU2017268460B2 (en) 2016-05-20 2023-12-14 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
MX2019006624A (es) * 2016-12-09 2019-08-01 Seattle Genetics Inc Anticuerpos bivalentes enmascarados por helices superenrolladas.
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
US20200115461A1 (en) * 2017-05-03 2020-04-16 Harpoon Therapeutics, Inc. Compositions and methods for adoptive cell therapies
KR102376863B1 (ko) 2017-05-12 2022-03-21 하푼 테라퓨틱스, 인크. 메소텔린 결합 단백질
WO2019036433A2 (en) 2017-08-16 2019-02-21 Bristol-Myers Squibb Company ANTIBODIES IN THE FORM OF PRODRUGS, PRODRUGS BASED THEREON, THEIR METHODS OF USE AND PREPARATION
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
WO2019222282A1 (en) * 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CA3114038A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
US20220251206A1 (en) 2019-06-11 2022-08-11 Bristol-Myers Squibb Company Anti-ctla4 antibody prodruggable (probody) at a cdr position
KR20220144841A (ko) 2020-02-21 2022-10-27 하푼 테라퓨틱스, 인크. Flt3 결합 단백질 및 사용 방법
CN113354715B (zh) * 2021-05-07 2023-03-17 暨南大学 Egfr的改造的结合蛋白及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902582A (en) * 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
CN101031588A (zh) * 2004-06-01 2007-09-05 多曼蒂斯有限公司 药物组合物，融合物和结合物
WO2006017325A2 (en) * 2004-07-13 2006-02-16 Cell Genesys, Inc. Aav vector compositions and methods for enhanced expression of immunoglobulins the same
US20060252096A1 (en) * 2005-04-26 2006-11-09 Glycofi, Inc. Single chain antibody with cleavable linker
WO2009021754A2 (en) * 2007-08-15 2009-02-19 Bayer Schering Pharma Aktiengesellschaft Monospecific and multispecific antibodies and method of use
EP3492488A1 (en) * 2007-08-22 2019-06-05 The Regents of The University of California Activatable binding polypeptides and methods of identification and use thereof
JP5714505B2 (ja) * 2008-12-22 2015-05-07 ノヴォ ノルディスク アー／エス 組織因子経路阻害因子に対する抗体
BRPI1006141B8 (pt) * 2009-01-12 2021-05-25 Cytomx Therapeutics Llc composições de anticorpo modificado, métodos para preparar e usar as mesmas
MX2012006406A (es) * 2009-12-04 2012-07-25 Genentech Inc Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
US20130052192A1 (en) * 2010-02-19 2013-02-28 Novo Nordisk A/S Activatable Constructs
PT2542257T (pt) * 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
EP3146977B1 (en) * 2010-03-19 2024-05-08 Takeda Pharmaceutical Company Limited Tfpi inhibitors and methods of use
WO2012001087A1 (en) * 2010-06-30 2012-01-05 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor

Also Published As

Publication number Publication date
CN105209496A (zh) 2015-12-30
HK1215262A1 (zh) 2016-08-19
US20160009817A1 (en) 2016-01-14
EP2970498A4 (en) 2016-11-23
WO2014144689A1 (en) 2014-09-18
EP2970498A1 (en) 2016-01-20
CA2906095A1 (en) 2014-09-18
UY35459A (es) 2014-10-31
TW201522368A (zh) 2015-06-16
JP2016514687A (ja) 2016-05-23

Similar Documents

Publication Publication Date Title
AR095502A1 (es) Anticuerpos profármaco contra el inhibidor de la vía del factor tisular
CY1124061T1 (el) Τρικυκλικη ενωση ως αντικαρκινικοι παραγοντες
NI201500094A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
CO2018001473A2 (es) Anticuerpos inhibidores de vía del factor tisular y usos de los mismos
CL2017000820A1 (es) Compuestos de aminopurina sustituida, composiciones de los mismos, y metodos de tratamiento con los mismos
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
DOP2015000234A (es) COMPOSICIONES DE ARNi CONTRA EL COMPONENTE C5 DEL COMPLEMENTO Y METODOS PARA SU USO.
PE20210949A1 (es) Anticuerpos anti-fgfr2iiib afucosilados
MX2016014253A (es) Inhibidores de desmetilasa-1 especifica de lisina.
UY35787A (es) Composiciones útiles para tratar trastornos relacionados con kit
EA201690549A1 (ru) Арилэфиры и их применения
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
CR20160200A (es) Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores
CR20170219A (es) Inhibidores del bromodominio
ECSP14030779A (es) Inhibidores del nampt
UY36747A (es) Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen
MX2016005294A (es) Metodos para tratar y prevenir enfermedad injerto contra huésped.
CL2017000317A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
UY35493A (es) Métodos para el tratamiento de la osteogénesis imperfecta
MX2017013074A (es) Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer.
MX373646B (es) Halogeno-pirazoles como inhibidores de trombina.
GT201300267A (es) Isoxazolinas como agentes terapéuticos

Legal Events

Date Code Title Description
FB Suspension of granting procedure